Patients can expect the same trusted support from Sanofi.


Sanofi’s support services represent our more than 35-year commitment to supporting the rare disease community. We are dedicated to our mission and will continue to provide the comprehensive support services that patients have relied on for years.

How to Start

Everything you need to know about starting treatment with NEXVIAZYME.


Billing and
Coding Guide

Understand how coverage and coding works for NEXVIAZYME.


Patient Discussion Guide

Help your patients prepare
for their next appointment.


Patient’s infusion process and center can stay the same

Patient’s infusion process and center can stay the same

The quickstart program support image

Sanofi may be able to help your patients start treatment

Your patient may be eligible for the QuickStart Program. The QuickStart CareConnectPSS® Program provides NEXVIAZYME to eligible, commercially insured patients. Patients can receive NEXVIAZYME at no charge while authorization is being reviewed, or in the event of coverage delays or denials. Examples include, but are not limited to:

  • Delays in prior insurance authorizations
  • Waiting for exceptions and appeal determinations
  • Reinitiation of prior insurance authorizations due to transitions to new health insurers

Certain eligibility restrictions apply:

  • Eligible patients may receive up to 4 infusions of NEXVIAZYME; in certain circumstances, eligibility may be extended


  • The patient’s healthcare provider must send the application for QuickStart (as indicated on the enrollment form)
  • Once coverage has been obtained, the CareConnectPSS QuickStart Program will transition the patient to the referring specialty pharmacy for commercial product

For more information, please call 1-800-745-4447, option 3, Monday through Friday, 8:00 AM-8:00 PM ET for more information

Check to see if your patient is eligible for QuickStart.



Sanofi also offers co-pay assistance and charitable access programs for eligible patients.
The Co-Pay Assistance Program helps individuals in the United States who are prescribed NEXVIAZYME pay for their eligible out-of-pocket drug and infusion-related (mixing and administration of the drug as well as infusion supplies such as saline, IV tubing, etc.) expenses, including co-pays, co-insurance, and deductibles.
To participate in this program your patients must complete an enrollment application.
If enrolled, Sanofi will cover 100% of their eligible out-of-pocket NEXVIAZYME drug costs, up to the program maximum.

Nexviazyme Co-Pay program image

The Co-Pay Program does not cover prescriptions eligible to be reimbursed, in whole or in part, by a state or federal health care program, including but not limited to Medicare, Medicare Advantage Plans (Example: FreedomBlue offered through BlueCross Blue Shield), Medicare Part D, Medicaid, Medigap, Veterans Affairs, Department of Defense, or TRICARE.
In accordance with State law, the Program does not reimburse infusion-related charges for commercially insured patients residing in Massachusetts or Rhode Island.
No claim for reimbursement of any out-of-pocket expenses covered by the Co-pay Program may be submitted to any third-party payer, whether public or private. The Co-pay Program is available only in the United States and cannot be combined with any other rebate/coupon, free trial, or similar offer. Co-pay benefits are not transferrable.
Sanofi reserves the right to rescind, revoke, modify, or amend this program without notice.

Patient Assistance Program

Qualified individuals with Pompe disease whose physicians have recommended treatment with NEXVIAZYME may be eligible for the Patient Assistance Program. Learn more about the CareConnectPSS Patient Assistance Program and download the application form.


There are numerous resources available to both healthcare providers and their patients to help contribute to their understanding of Pompe disease.

Professional and patient organizations can help educate and bring together those in the Pompe community, and Sanofi offers years of expertise and resources for managing and living with this disease. Sanofi is committed to providing practitioners with information and access to resources that continue to help improve standards of care for patients with Pompe disease.

The Pompe Registry

This ongoing, observational database sponsored by Sanofi tracks the natural history and outcomes of patients with Pompe disease. All patients with Pompe disease are eligible for enrollment irrespective of their treatment status, and all physicians managing patients with Pompe disease are encouraged to learn about the Pompe Registry.